Evidence map›Paper›PMID 31325600›Full record

ArticleJournal of ethnopharmacology2019

Evaluation of potential herb-drug interactions between oseltamivir and commonly used anti-influenza Chinese medicinal herbs.

Yufeng Zhang, Chunming Lyu, Sophia Yui Kau Fong, Qian Wang, Chenrui Li, Nicolas James Ho, Kay Sheung Chan, Xiaoyu Yan, Zhong Zuo

Open access · bronzeAbstract read
In one paragraph

Article in Journal of ethnopharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Rutin andPharmaceutics · 2024
    Article
  4. Review
  5. Article
  6. Review
  7. Mechanism ofAnnals of translational medicine · 2022
    Article
  8. Article
  9. Article
  10. Genetic Toxicology and Safety Pharmacological Evaluation of Forsythin.Evidence-based complementary and alternative medicine : eCAM · 2021
    Article
  11. Review
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Yufeng ZhangSchool of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong Special Administrative Region. Electronic address: zhangyf@cuhk.edu.hk.
Chunming LyuSchool of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong Special Administrative Region. Electronic address: chunming83g@126.com.
Sophia Yui Kau FongSchool of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong Special Administrative Region. Electronic address: sfong@cuhk.edu.hk.
Qian WangSchool of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong Special Administrative Region. Electronic address: wangqianxinwei@163.com.
Chenrui LiSchool of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong Special Administrative Region. Electronic address: chenruilee525@126.com.
Nicolas James HoSchool of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong Special Administrative Region. Electronic address: nicolas.james@cuhk.edu.hk.
Kay Sheung ChanDepartment of Microbiology, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong Special Administrative Region. Electronic address: paulkschan@cuhk.edu.hk.
Xiaoyu YanSchool of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong Special Administrative Region. Electronic address: xiaoyuyan@cuhk.edu.hk.
Zhong ZuoSchool of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong Special Administrative Region. Electronic address: joanzuo@cuhk.edu.hk.
Chinese University of Hong Kong · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

ethnopharmacological relevanceAccording to Traditional Chinese Medicine theory, influenza is categorized as a warm disease or Wen Bing. The Wen Bing formulas, such as Yin-Qiao-San and Sang-Ju-Yin, are still first-line herbal therapies in combating variant influenza virus. To continue our study on the pharmacokinetic and pharmacodynamic interactions between Wen Bing formulas and oseltamivir (OS), the first-line western drug for the treatment of influenza, further interactions between OS and the eight single herbs and their relevant marker components from Wen Bing formulas were investigated in the current study. AIM OF STUDY: To establish an in-vitro screening platform for investigation of the potential anti-influenza herbs/herbal components that may have pharmacokinetic and pharmacodynamic interactions with OS. MATERIALS AND

methodsTo screen potential inhibition on OS hydrolysis, 1 μg/mL of OS is incubated with herbs/herbal components in diluted rat plasma, microsomes and human recombinant carboxylesterase 1(hCE1) under optimized conditions. MDCK-WT and MDCK-MDR1 cell lines are utilized to identify potential modification on P-gp mediated transport of OS by herbs/herbal components. Caco-2 cells with and without Gly-Sar inhibition are performed to study the uptake of OS via PEPT1 transporters. Modification on OAT3 mediated transport is verified by the uptake of OS on HEK293-MOCK/HEK293-OAT3 cells. Anti-virus effects were evaluated using plaque reduction assay on H1N1 and H3N2 viruses. Potential pharmacokinetic and pharmacodynamic interaction between OS (30 mg/kg) and the selected herb, Radix Scutellariae (RS), at 300-600 mg/kg were carried out on rats. All samples are analyzed by an LC/MS/MS method for the contents of OS and OSA. A mechanistic PK model was developed to interpret the HDI between OS and RS in rats.

resultsOur developed platform was successfully applied to screen the eight herbal extracts and their ten marker components on metabolic inhibition of OS and modification of OS transport mediated by P-gp, OAT3 and PEPT1. Results from six in-vitro experiments were analyzed after converting raw data from each experiment to corresponding fold-change (FC) values, based on which Radix Scutellariae (RS) were selected to have the most HDI potential with OS. By analyzing the plasma and urine pharmacokinetic data after co-administration of OS with a standardized RS extract in rats using an integrated population pharmacokinetics model, it is suggested that RS could inhibit OS hydrolysis during absorption and increase the absorbed fraction of OS, which leads to the increased ratio of OS concentration versus that of OSA in both rat plasma and urine. Never the less, the anti-virus effects of 2.5 h post-dose rat plasma were not influenced by co-administration of OS with RS.

conclusionA six-dimension in-vitro screening platform has been developed and successfully applied to find RS as a potential herb that would influence the co-administrated OS in rats. Although co-administered RS could inhibit OS hydrolysis during absorption and increase the absorbed fraction of OS, which lead to the increased ratio of OS concentration versus that of OSA in both rat plasma and urine, the anti-virus effect of OS was not influenced by co-administered RS.

Indexed as

Herb-Drug InteractionsScutellaria baicalensisAnimalsAntiviral AgentsATP Binding Cassette Transporter, Subfamily B, Member 1Caco-2 CellsDogsDrugs, Chinese HerbalHEK293 CellsHumansInfluenza A Virus, H1N1 SubtypeInfluenza A Virus, H3N2 SubtypeMadin Darby Canine Kidney CellsMaleMedicine, Chinese TraditionalMicrosomes, LiverAntiviral AgentsATP Binding Cassette Transporter, Subfamily B, Member 1Drugs, Chinese HerbalOrganic Anion Transporters, Sodium-Independentorganic anion transport protein 3OseltamivirArctiin (PubChem CID: 100528)Baicalein (PubChem CID: 5281605)Baicalin (PubChem CID: 64982)Chlorogenic acid (PubChem CID: 1794427)Epigoitrin (PubChem CID: 3032313)Glycyrrhizic acid (PubChem CID: 14982)Herb-drug interactionsLiquirtin (PubChem CID: 503737)OseltamivirOseltamivir acid (PubChem CID: 449381)Oseltamivir (PubChem CID: 78000)Phillyrin (PubChem CID: 101712)Population pharmacokinetics modelingRadix ScutellariaeRutin (PubChem CID: 5280805)Traditional Chinese medicineWogonin (PubChem CID: 5281703)

Identifiers

PMID31325600
PMCPMC7125811
OpenAlexW2957308979

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.